Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. The company's portfolio includes ORKA-001, a high-affinity, extended half-life monoclonal antibody targeting the p19 subunit of interleukin-23 for the treatment of psoriasis, and ORKA-002, a co-lead program targeting interleukin-17A and interleukin-17F for psoriasis, hidradenitis suppurativa, and psoriatic arthritis. Both product candidates incorporate half-life extension technology to support reduced dosing frequencies. The company was formerly known as ARCA biopharma, Inc. and completed the acquisition of Pre-Merger Oruka in August 2024. Oruka Therapeutics is currently advancing these programs through Phase 1 and Phase 2 clinical trials, with the goal of improving efficacy and dosing regimens for patients with chronic skin diseases.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage orukatx.com
Sector Healthcare IR page orukatx.com
Tags
monoclonal antibodies, psoriasis, inflammatory and immunology, hidradenitis suppurativa, psoriatic arthritis, half-life extension, interleukin-23, interleukin-17, clinical-stage, biologics, ORKA-001, ORKA-002, EVERLAST-A, EVERLAST-B, ORCA-SURGE, ARCA biopharma Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC, Oruka Therapeutics Operating Company LLC, Paragon Therapeutics Inc., Fairmount Funds Management LLC
Press page —

Metrics

Valuation  
Market cap $ 7.034B
Market cap (USD) $ 7.034B
P/E -46.10
PEG —
P/BV 5.88
P/S —
P/OCF -56.89
P/FCF -56.79
Dividend yield —
Turnover / mcap —
Returns  
ROE -24.7%
ROI -24.7%
ROIC -21.5%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024
Assets 488.617M 396.019M
Net profit -105.433M -83.724M
Free cash flow -88.419M -58.026M

Figure FY 2025 FY 2024
Share price 30.31 19.39
Price performance 12m 0.56 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 25,000 450,000 483,000 383,000 280,000 968,000 1.93M
Cash and deposits (USD) 7.4M 8.7M 6.61M 8.36M 49.1M 53.4M 42.4M 37.4M 61.6M 46.9M
Right-of-use assets (USD) — — — 22,000 428,000 437,000 343,000 247,000 876,000 1.83M
Cash flow detail
Operating cash flow (USD) -15M -17.5M -8.24M -4.8M -7.73M -18.8M -10.9M -5.01M -57.8M -88.2M
Purchases of property, plant and equipment (USD) -12,000 -3,000 -4,000 -4,000 -19,000 -43,000 -2,000 0.00 -189,000 -209,000
Change in payables (cash effect) (USD) 841,000 -583,000 -392,000 188,000 1.1M -411,000 -783,000 28,000 — —
Interest paid (cash effect) (USD) — -6,000 -8,000 -7,000 -9,000 — — — — —
Share-based compensation (USD) 576,000 458,000 273,000 151,000 43,000 497,000 556,000 686,000 14.9M 24.2M
Free cash flow (OCF - PPE - intangibles) (USD) -15M -17.5M -8.25M -4.81M -7.74M -18.8M -10.9M -5.01M -58M -88.4M
Income detail
Research and development expense (USD) 12.3M 14.1M 4.24M 1.83M 4.99M 13.8M 4.75M 1.01M 75.1M 101M
↳ 5y CAGR +39.8% +66.7% +7.7% -20.1% -6.7% +2.3% -19.5% -24.9% +110.1% +82.3%
Total comprehensive income (USD) -16.5M -18.5M -7.93M -5.48M — — — — -83.8M -105M
Comprehensive income to owners (USD) -16.5M -18.5M -7.93M -5.48M — — — — -83.8M -105M
Reported Mar 21, 2017 Mar 22, 2018 Feb 27, 2019 Feb 18, 2020 Mar 18, 2021 Mar 14, 2022 Feb 24, 2023 Feb 1, 2024 Mar 6, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences:

Guggenheim 3rdAnnual Healthcare Innovation Conference Date: November 10, 2026 **Presentation Time:**11:00 AM EST

Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST

UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT

Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT

Webcasts and replays of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: Alan Lada (650)-606-7911 [email protected]

Search Investors

October 26, 2026

PDF Version

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A

Continued favorable safety and tolerability profile consistent with the IL-23p19 class

ORKA-001 on track to advance into Phase 3 trials in 1H 2027

52-week EVERLAST-A results on track for December 2026

ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027

Management to host conference call today at 8:00 a.m. ET

MENLO PARK, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Oruka) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe PsO.

“We are incredibly pleased with the remarkable profile of ORKA-001 observed to date, with highly consistent results achieved across EVERLAST-B and EVERLAST-A. These results further solidify our confidence that ORKA-001 could become the preferred medicine for psoriasis, with high rates of complete skin clearance, a favorable safety profile, and potential for dosing once to twice per year,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “The data shared today support our next step: engaging with regulatory agencies as we advance ORKA-001 towards Phase 3 trials, which we plan to initiate in the first half of next year.”

“These results suggest ORKA-001 is likely to be the most effective IL-23-targeting biologic to date,” said Joel Gelfand, MD, MSCE, FAAD, James J. Leyden Professor of Dermatology and Epidemiology at the University of Pennsylvania and lead investigator for EVERLAST-B. “Virtually all patients could expect to have a very good response, and the majority could expect to achieve completely clear skin within just 16 weeks. The potential for these effects to be long lasting, with just one or two doses a year, would be a paradigm shift in moderate-to-severe psoriasis management, allowing for the trifecta of clear skin, convenience, and excellent safety that would further elevate the standard of care we can offer our patients.”

EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b trial evaluating the safety, efficacy, and pharmacokinetics of ORKA-001 in patients with moderate-to-severe PsO. The trial is being conducted across 36 sites in the United States, Canada, and Europe. Less than 30% of these sites participated in EVERLAST-A. EVERLAST-B enrolled 187 patients randomized 1:1:1:1 to receive 37.5 mg ORKA-001 at Week 0 (low dose), 300 mg ORKA-001 at Weeks 0 and 4 (mid dose), 600 mg ORKA-001 at Weeks 0 and 4 (high dose), or placebo. The primary endpoint is PASI 100 at Week 16. At Week 28, patients receiving ORKA-001 who have achieved PASI 100 will be re-randomized 1:1 to either 600 mg ORKA-001 once yearly or placebo. Patients who have not achieved PASI 100 will receive 300 mg ORKA-001 every six months. The study continues through Week 100 to assess durability of response, maintenance dosing, and long-term safety.

Efficacy

Efficacy increased in a dose-dependent manner across ORKA-001 treatment groups, with the high-dose (600 mg) group outperforming both lower dose groups on complete skin clearance. 61% of patients in the high-dose group achieved the primary endpoint of PASI 100 at Week 16, compared to 0% of patients receiving placebo (p<0.0001). The ORKA-001 high-dose group demonstrated high response rates across secondary endpoints, including 86% of patients achieving PASI 90 and IGA 0/1, consistent with the results observed in EVERLAST-A.

| Week 16 | Placebo (N=47) | Low dose (N=47) | Mid dose (N=47) | High dose (N=46) |

| PASI 100 | 0% | 43% | 44% | 61% |

| PASI 90 | 0% | 70% | 85% | 86% |

| IGA 0/1 | 0% | 74% | 85% | 86% |

| |

Safety

ORKA-001 continues to be well tolerated, with a safety profile consistent with the IL-23p19 class. The overall rate of treatment-emergent adverse events (TEAEs) was comparable across groups, with 39% of patients in the high-dose group experiencing at least one TEAE, versus 43% of participants receiving placebo. The only TEAEs occurring in ≥5% of patients treated with ORKA-001 were upper respiratory tract infection and headache, occurring at rates similar to those seen with approved IL-23 inhibitors. No dose-dependent trends in adverse events were observed across ORKA-001 treatment groups, and no injection-site reactions occurred in any patients who received ORKA-001.

| Week 0-16 | Placebo (N=47) | Low dose (N=47) | Mid dose (N=47) | High dose (N=46) | All ORKA-001 (N=140) |

| ≥1 TEAE, n (%) | 20 (43%) | 22 (47%) | 28 (60%) | 18 (39%) | 68 (49%) |

| ≥1 serious TEAE, n (%) | 2 (4%) | 1 (2%) | 2 (4%) | - | 3 (2%) |

| ≥1 severe TEAE, n (%) | 2 (4%) | 1 (2%) | 2 (4%) | - | 3 (2%) |

| Discontinuation due to TEAE, n (%) | 1 (2%) | 1 (2%) | 1 (2%) | - | 2 (1%) |

| Most frequent TEAEs, n (%) |

| Upper respiratory tract infection | 4 (9%) | 5 (11%) | 9 (19%) | 6 (13%) | 20 (14%) |

| Headache | 1 (2%) | 2 (4%) | 3 (6%) | 3 (7%) | 8 (6%) |

| Injection site reactions, n (%) | 1 (2%) | - | - | - | - |

| |

No serious TEAEs occurred in the high-dose group. Serious TEAEs occurring in the other groups were kidney stones, miscarriage, psoriasis, substance-induced psychotic disorder, and syncope following a blood draw and jaw fracture. None were considered treatment related.

Upcoming Milestones for ORKA-001

Based on the results from the EVERLAST clinical program, the company intends to discuss Phase 3 plans with regulatory authorities. Pending results from those discussions, Oruka plans to initiate Phase 3 trials of ORKA-001 in moderate-to-severe PsO in the first half of 2027 with the high dose (600 mg). In addition, Oruka expects to share 52-week results from EVERLAST-A in December 2026, as well as 52-week results from EVERLAST-B in the second half of 2027.

Webcast Details

Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin today at 8:00 a.m. ET. The live webcast can be accessed via this link,or through the Investors section on the company’s website at https://ir.orukatx.com/news-events/events-presentations. A replay of the webcast will be available following the call.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Forward-Looking Statements

Certain statements in this press release, other than statements of historical fact, are “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, efficacy, safety, tolerability, durability of response and dosing profile of ORKA-001; the potential for ORKA-001 to provide durable disease control with infrequent dosing; the planned conduct, progress, timing and results of the EVERLAST-A and EVERLAST-B trials; and the anticipated timing of clinical data readouts and ORKA-001 Phase 3 trial commencement. These forward-looking statements are based on Oruka’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law.

Investor Contact:

Alan Lada (650) 606-7911 [email protected]

Search Investors

October 25, 2026

PDF Version

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details

Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin on Monday, October 26th, at 8:00 a.m. ET. The live webcast can be accessed via this link, or through the Investors section on the company’s website at https://ir.orukatx.com/news-events/events-presentations. A replay of the webcast will be available following the call.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: Alan Lada (650)-606-7911 [email protected]

Search Investors

Prompts

Oruka Therapeutics, Inc. (ticker ORKA), listed in United States.

Company History

Date Change Detail
Sep 5, 2024 Renamed ARCA BIOPHARMA, INC. → ORUKA THERAPEUTICS, INC.
Jan 28, 2009 Renamed NUVELO INC → ARCA BIOPHARMA, INC.
Feb 4, 2003 Renamed HYSEQ INC → NUVELO INC
— Former tickers ABIO

ETFs Holding Oruka Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FMED 1.08% 6,000 $ 555.72K Aug 31, 2026
JSML 0.76% 28,596 $ 2.76M Jul 31, 2026
JSMD 0.75% 82,097 $ 7.923M Jul 31, 2026
MEDI 0.70% 3,145 $ 330.194K Nov 12, 2026
CGMM 0.52% 189,723 $ 18.828M Nov 16, 2026
TCAL 0.45% 15,065 $ 1.495M Nov 17, 2026
AFSM 0.43% 6,335 $ 628.685K Nov 16, 2026
RUSC 0.40% 3,368 $ 320.533K Jun 30, 2026
SCDS 0.33% 313 $ 30.148K Nov 17, 2026
TMED 0.31% 746 $ 70.997K Jun 30, 2026
MSSM 0.29% 22,184 $ 2.055M Aug 31, 2026
TCAF 0.22% 239,847 $ 23.802M Nov 17, 2026
VFMO 0.19% 39,118 $ 3.623M Aug 31, 2026
FFSM 0.17% 26,725 $ 2.579M Jul 31, 2026
RESM 0.15% 59 $ 5,615.03 Jun 30, 2026
FESM 0.07% 42,994 $ 4.092M Jun 30, 2026
DFAS 0.02% 60,499 $ 6.352M Nov 12, 2026
DFUS 0.00% 1,553 $ 163.049K Nov 12, 2026
AVUS 0.00% 263 $ 26.1K Nov 16, 2026
AVSU 0.00% 67 $ 6,649.08 Nov 16, 2026
IALT short 0.00% -1,889 $ -187.464K Nov 16, 2026
AVLC 0.00% 48 $ 4,763.52 Nov 16, 2026
NTRL short 0.00% -450 $ 0.00 Nov 16, 2026